Osimertinib maintenance after chemotherapy – pro
Osimertinib is currently approved by the U.S. Food and Drug Administration as first-line treatment of EGFR-mutated advanced NSCLC and second-line treatment of EGFR T790M mutationpositive advanced NSCLC.
AS REPORTED in The New England Journal of Medicine by Jean-Charles Soria, MD, PhD, of Gustave Roussy Cancer Campus and University Paris-Sud, and colleagues, the phase III FLAURA trial has shown a significant progression-free survival benefit with the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso) vs standard EGFR TKIs in previously untreated advanced EGFR-mutant nonsmall cell lung cancer (NSCLC)
Treatment with targeted therapy osimertinib (Tagrisso) following surgery for localized non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation significantly improved disease-free survival in a phase III study.
Adjuvant osimertinib significantly improved disease-free survival compared with placebo in patients with stage IB to IIIA EGFR-mutated nonsmall cell lung cancer (NSCLC) who underwent complete resection of primary tumor and received chemotherapy if indicated.
The ADAURA trial results will likely move osimertinib up from the front-line setting to earlier in the adjuvant setting in patients who have undergone complete resection.
What is missing is the use of this drug after chemotherapy for maintemanceas is being done here. We do not have data on this approach at this time.
Liam CK. The role of osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer. J Thorac Dis. 2019;11(Suppl 3):S448-S452. doi:10.21037/jtd.2018.11.45
Soria JC, Ohe Y, Vansteenkiste J, et al: Osimertinib in untreated EGFR-mutated advanced nonsmall-cell lung cancer. N Engl J Med 378:113-125, 2018.